GSK (GSK) Expected to Release Quarterly Earnings on Tuesday

GSK (NYSE:GSK) is projected to announce its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect GSK to post earnings of $1.27 per share and revenue of $11.0198 billion for the quarter. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 9:00 AM ET.

GSK Stock Performance

GSK stock opened at $50.04 on Tuesday. The company has a market capitalization of $101.22 billion, a P/E ratio of 13.01, a PEG ratio of 3.31 and a beta of 0.35. The company has a 50-day simple moving average of $51.56 and a 200 day simple moving average of $53.37. GSK has a fifty-two week low of $36.19 and a fifty-two week high of $61.69. The company has a quick ratio of 0.52, a current ratio of 0.79 and a debt-to-equity ratio of 0.80.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, July 9th. Shareholders of record on Friday, May 15th were given a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date was Friday, May 15th. GSK’s payout ratio is 46.49%.

Analysts Set New Price Targets

GSK has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of GSK from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Royal Bank Of Canada reissued an “outperform” rating on shares of GSK in a report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research note on Thursday, July 9th. Weiss Ratings cut GSK from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 11th. Finally, HSBC raised GSK from a “reduce” rating to a “hold” rating in a research note on Monday, July 6th. Three analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $53.00.

Institutional Trading of GSK

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ameriprise Financial Inc. boosted its holdings in GSK by 1.2% during the second quarter. Ameriprise Financial Inc. now owns 401,777 shares of the pharmaceutical company’s stock worth $15,444,000 after buying an additional 4,855 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of GSK by 28.2% during the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company’s stock valued at $4,656,000 after purchasing an additional 26,685 shares during the last quarter. Align Financial LLC acquired a new position in shares of GSK in the 4th quarter valued at $5,628,000. Arkadios Wealth Advisors increased its stake in GSK by 59.0% in the 4th quarter. Arkadios Wealth Advisors now owns 107,379 shares of the pharmaceutical company’s stock worth $5,266,000 after purchasing an additional 39,863 shares in the last quarter. Finally, Captrust Financial Advisors increased its stake in GSK by 11.0% in the 2nd quarter. Captrust Financial Advisors now owns 85,080 shares of the pharmaceutical company’s stock worth $3,267,000 after purchasing an additional 8,432 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.